Synthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B Moraxella catarrhalis

Infection and Immunity

Volumn 73, Issue 5, 2005, Pages 2790-2796

  Yu, Shengqing ^a   Gu, Xin Xing ^a,b  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; BACTERIAL VACCINE; COMPLEMENT; DIPHTHERIA TOXIN; IMMUNOGLOBULIN G ANTIBODY; LIPOOLIGOSACCHARIDE; LIPOOLIGOSACCHARIDE DIPHTHERIA TOXIN CONJUGATE VACCINE; LIPOOLIGOSACCHARIDE TETANUS TOXOID CONJUGATE VACCINE; RABBIT ANTISERUM; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIGENICITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; CROSS REACTION; DETOXIFICATION; DRUG CONJUGATION; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNIZATION; INHIBITION KINETICS; MORAXELLA CATARRHALIS; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; RABBIT; WEIGHT;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; BLOOD BACTERICIDAL ACTIVITY; CARBOHYDRATE SEQUENCE; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNIZATION; LIPOPOLYSACCHARIDES; MICE; MOLECULAR SEQUENCE DATA; MORAXELLA (BRANHAMELLA) CATARRHALIS; MORAXELLACEAE INFECTIONS; RABBITS; SEROTYPING; TETANUS TOXOID; VACCINES, CONJUGATE;

EID: 17644401770     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.73.5.2790-2796.2005     Document Type: Article

References (59)

1. Aebi, C., L. D. Cope, J. L. Latimer, S. E. Thomas, C. A. Slaughter, G. H. J. McCracken, and E. J. Hansen. 1998. Mapping of a protective epitope of the CopB outer membrane protein of Moraxella catarrhalis. Infect. Immun. 66:540-548.
2. Adlowitz, D. G., T. Hiltke, A. J. Lesse, and T. F. Murphy. 2004. Identification and characterization of outer membrane proteins G1a and G1b of Moraxella catarrhalis. Vaccine 22:2533-2540.
3. Ahmed, K., N. Rikitomi, A. Ichinose, and K. Matsumoto. 1991. Possible presence of a capsule in Branhamella catarrhalis. Microbiol. Immunol. 35:361-366.
4. Bluestone, C. D. 1986. Otitis media and sinusitis in children. Role of Branhamella catarrhalis. Drugs 31(Suppl. 3):132-141.
5. Catlin, B. W. 1990. Branhamella catarrhalis: an organism gaining respect as a pathogen. Clin. Microbiol. Rev. 3:293-320.
6. Chen, D., V. Barniak, K. R. Vandermeid, and J. C. McMichael. 1999. The levels and bactericidal capacity of antibodies directed against the UspA1 and UspA2 outer membrane proteins of Moraxella (Branhamella) catarrhalis in adults and children. Infect. Immun. 67:1310-1316.
7. Chen, D., J. C. McMichael, K. R. VanDerMeid, D. Hahn, T. Mininni, J. Cowell, and J. Eldridge. 1996. Evaluation of purified UspA from Moraxella catarrhalis as a vaccine in a murine model after active immunization. Infect. Immun. 64:1900-1905.
8. Chen, D., J. C. McMichael, K. R. VanDerMeid, A. W. Masi, E. Bortell, J. D. Caplan, D. N. Chakravarti, and V. L. Barniak. 1999. Evaluation of a 74-kDa transferrin-binding protein from Moraxella (Branhamella) catarrhalis as a vaccine candidate. Vaccine 20:109-118.
9. Cohen, D., S. Ashkenazi, M. S. Green, M. Gdalevich, G. Robin, R. Slepon, M. Yavzori, N. Orr, C. Block, I. Ashkenazi, J. Shemer, D. N. Taylor, T. L. Hale, J. C. Sadoff, D. Pavliakova, R. Schneerson, and J. B. Robbins. 1997. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet 349:155-159.
10. Doyle, W. J. 1989. Animal models of otitis media: other pathogens. Pediatr. Infect. Dis. J. 81(Suppl.):S45-S47.
11. Dubois, M., H. Gillis, J. K. Hamilton, A. A. Rebers, and R. Smith. 1956. Colorimetric method for the determination of sugars and related substances. Anal. Biochem. 28:250-256.
12. Edebrink, P., P. E. Jansson, M. M. Rahman, G. Widmalm, T. Holme, and M. Rahman. 1995. Structural studies of the O-antigen oligosaccharides from two strains of Moraxella catarrhalis serotype C. Carbohydr. Res. 266:237-261.
13. Edebrink, P., P. E. Jansson, M. M. Rahman, G. Widmalm, T. Holme, M. Rahman, and A. Weintraub. 1994. Structural studies of the O-polysaccharide from the lipopolysaccharide of Moraxella (Branhamella) catarrhalis serotype A (strain ATCC 25238). Carbohydr. Res. 257:269-284.
14. Edebrink, P., P. E. Jansson, G. Widmalm, T. Holme, and M. Rahman. 1996. The structures of oligosaccharides isolated from the lipopolysaccharide of Moraxella catarrhalis serotype B, strain CCUG 3292. Carbohydr. Res. 295:127-146.
15. Enright, M. C., and H. McKenzie. 1997. Moraxella (Branhamella) catarrhalis-clinical and molecular aspects of a rediscovered pathogen. J. Med. Microbiol. 46:360-371.
16. Faden, H., J. Bernstein, L. Brodsky, J. Stanievich, D. Krystofik, C. Snuff, J. J. Hong, and P. L. Ogra. 1989. Otitis media in children. I. the systemic immune response to nontypable Haemophilus influenzae. J. Infect. Dis. 160:999-1004.
17. Faden, H., Y. Harabuchi, and J. J. Hong. 1994. Epidemiology of Moraxella catarrhalis in children during the first 2 years of life: relationship to otitis media. J. Infect. Dis. 169:1312-1317.
18. Faden, H., J. Hong, and T. F. Murphy. 1992. Immune response to outer membrane antigens of Moraxella catarrhalis in children with otitis media. Infect. Immun. 60:3824-3829.
19. Fomsgaard, J. S., A. Fomsgaard, N. Hoiby, B. Bruun, and C. Galanos. 1991. Comparative immunochemistry of lipopolysaccharides from Branhamella catarrhalis strains. Infect. Immun. 59:3346-3349.
20. Forsgren, A., M. Brant, M. Karamehmedovic, and K. Riesbeck. 2003. The immunoglobulin D-binding protein MID from Moraxella catarrhalis is also an adhesin. Infect. Immun. 71:3302-3309.
21. Gu, X.-X., J. Chen, S. J. Barenkamp, J. B. Robbins, C.-M. Tsai, D. J. Lim, and J. Battery. 1998. Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis. Infect. Immun. 66:1891-1897.
22. Gu, X.-X., J. Sun, S. Jin, S. J. Barenkamp, D. J. Lim, J. B. Robbins, and J. Battey. 1997. Detoxified lipooligosaccharide from nontypable Haemophilus influenzae conjugated to proteins confers protection to otitis media in chinchillas. Infect. Immun. 65:4488-4493.
23. Gu, X.-X., and C.-M. Tsai. 1993. Preparation, characterization, and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharide- protein conjugate. Infect. Immun. 61:1873-1880.
24. Gu, X.-X., C.-M. Tsai, T. Ueyama, S. J. Barenkamp, J. B. Robbins, and D. J. Lim. 1996. Synthesis, characterization, and immunological properties of detoxified lipooligosaccharide from nontypable Haemophilus influenzae conjugated to proteins. Infect. Immun. 64:4047-4053.
25. Helminen, M. E., I. Maciver, J. L. Latimer, L. D. Cope, G. H. J. McCracken, and E. J. Hansen. 1993. A major outer membrane protein of Moraxella catarrhalis is a target for antibodies that enhance pulmonary clearance of the pathogen in an animal model. Infect. Immun. 61:2003-2010.
26. Helminen, M. E., I. Maciver, J. L. Latimer, J. Klesney-Tait, L. D. Cope, M. Paris, G. H. McCracken, and E. J. Hansen. 1994. A large, antigenically conserved protein on the surface of Moraxella catarrhalis is a target for protective antibodies. J. Infect. Dis. 170:867-872.
27. Holm, M. M., S. L. Vanlerberg, I. M. Foley, D. D. Sledjeski, and E. R. Lafontaine. 2004. The Moraxella catarrhalis porin-like outer membrane protein CD is an adhesin for human lung cells. Infect. Immun. 72:1906-1913.
28. Holme, T., M. Rahman, P. E. Jansson, and G. Widmalm. 1999. The lipooligosaccharide of Moraxella catarrhalis: structural relationships and antigenic properties. Eur. J. Biochem. 265:524-529.
29. Hu, W.-G, J. Berry, J. Chen and X.-X Gu. 2004. Exploration of Moraxella catarrhalis Outer Membrane Proteins. CD and UspA, as New Carriers for Lipooligosaccharide-based Conjugates. FEMS Immunol. Med. Microbiol. 41:109-115.
30. Hu, W.-G., J. Chen, J. F. Battey and X.-X. Gu. 2000. Enhancement of clearance of bacteria from murine lungs by immunization with detoxified lipooligosaccharide from Moraxella catarrhalis conjugated to proteins. Infect. Immun. 68:4980-4985.
31. Hu, W.-G., J. Chen, J. C. McMichael and X.-X Gu. 2001. Functional characteristics of a protective monoclonal antibody against serotype A and C lipooligosaccharides from Moraxella catarrhalis. Infect. Immun. 69:1358-1363.
32. Jiao, X., H. Takashi, Y. Hou, and X.-X. Gu. 2002. Specific immune responses and enhancement of murine pulmonary clearance of Moraxella catarrhalis by intranasal immunization with a detoxified lipooligosacchride conjugate vaccine. Infect. Immun. 70:5982-5989.
33. Kemp, A. H., and M. R. A. Morgan. 1986. Studies on the detrimental effects of bivalent binding in a microtiter plate ELISA and possible remedies. J. Immunol. Methods. 94:65-72.
34. Leibovitz, E. 2003. Acute otitis media in pediatric medicine: current issues in epidemiology, diagnosis, and management. Paediatr. Drugs 5(Suppl. 1):1-12.
35. Makela, P. H., P. Karma, M. Sipila, J. Pukander, and M. Leinonen. 1983. Possibilities of preventing otitis media by vaccination. Scand. J. Infect. Dis. Suppl. 39:34-38.
36. Marrs, C. F., and S. Weir. 1990. Pili (fimbriae) of Branhamella species. Am. J. Med. 88(Suppl 5A):36S-40S.
37. Masoud, H., M. B. Perry, J. R. Brisson, D. Uhrin, and J. C. Richards. 1994. Structural elucidation of the backbone oligosaccharide for the lipopolysaccharide of Moraxella catarrhalis serotype A. Can. J. Chem. 72:1466-1477.
38. Masoud, H., M. B. Perry, and J. C. Richards. 1994. Characterization of the lipopolysaccharide of Moraxella catarrhalis. Structural analysis of the lipid A from M. catarrhalis serotype A lipopolysaccharide. Eur. J. Biochem. 220:209-216.
39. McMichael J. C. 2000 Vaccines for Moraxella catarrhalis. Vaccine 19:S101-107.
40. Murphy, T. F., J. M. Kyd, A. John, C. Kirkham, and A. W. Cripps. 1998. Enhancement of pulmonary clearance of Moraxella (Branhamella) catarrhalis following immunization with outer membrane protein CD in a mouse model. J. Infect. Dis. 178:1667-1675.
41. Oishi, K., H. Tanaka, F. Sonoda, S. Borann, K. Ahmed, Y. Utsunomiya, K. Watanabe, T. Nagatake, M. Vaneechoutte, G. Verschraegen, and K. Matsumoto. 1996. A monoclonal antibody reactive with a common epitope of Moraxella (Branhamella) catarrhalis lipopolysaccharides. Clin. Diagn. Lab. Immunol. 3:351-354.
42. Rahman, M., T. Holme, I. Jonsson, and A. Krook. 1995. Lack of serotype-specific antibody response to lipopolysaccharide antigens of Moraxella catarrhalis during lower respiratory tract infection. Eur. J. Clin. Microbiol. Infect. Dis. 14:297-304.
43. Rahman, M., A. B. Jonsson, and T. Holme. 1998. Monoclonal antibodies to the epitope α-Gal-(1-4)-β-Gal-(1- of Moraxella catarrhalis LPS react with a similar epitope in type IV pili of Neisseria meningitidis. Microb. Pathog. 24:299-308.
44. Robbins, J. B., R. Schneerson, and S. C. Szu. 1995. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 171:1387-1398.
45. Ruuskanen, O., and T. Heikkinen. 1994. Otitis media: etiology and diagnosis. Pediatr. Infect. Dis. J. 13:S23-S26.
46. Sethi, S., and T. F. Murphy. 2001. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the art review. Clin. Microbiol. Rev. 14:336-363.
47. Shiloach, J., and J. B. Kaufman. 1999. The combined use of expanded bed volume adsorption and gradient elution for capture and partial purification of mutant diphtheria toxin (CRM9) from Corynebacterium diphtheriae. Sep. Sci. Technol. 34:29-40.
48. Shurin, P. A., J. M. Rehmus, C. E. Johnson, C. D. Marchant, S. A. Carlin, D. M. Super, G. F. Van Hare, P. K. Jones, D. M. Ambrosino, and G. R. Siber. 1993. Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high-risk children. J. Pediatr. 123:801-810.
49. Smith, P. K., R. I. Krohn, G. T. Hermanson, A. K. Mallia, F. H. Gartner, M. D. Provenzano, E. K. Fujimoto, N. M. Goeke, B. J. Olson, and D. C. Klenk. 1985. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150:76-85.
50. Tanaka, H., K. Oishi, F. Sonoda, A. Iwagaki, T. Nagatake, and K. Matsumoto. 1992. Biochemical analysis of lipopolysaccharides from respiratory pathogenic Branhamella catarrhalis strains and the role of anti-LPS antibodies in Branhamella respiratory infections. J. Jpn. Assoc. Infect. Dis. 66:709-715.
51. Timpe, J. M., M. M. Holm, S. L. Vanlerberg, V. Basrur, and E. R. Lafontaine. 2003. Identification of a Moraxella catarrhalis outer membrane protein exhibiting both adhesin and lipolytic activities. Infect. Immun. 71:4341-4350.
52. Tsai, C. M., and C. E. Frasch. 1982. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal. Biochem. 119:115-119.
53. Unhanand, M., I. Maciver, O. Ramilo, O. Arencibia-Mireles, J. C. Argyle, G. H. McCracken, and E. J. Hansen. 1992. Pulmonary clearance of Moraxella catarrhalis in an animal model. J. Infect. Dis. 165:644-650.
54. Vaneechoutte, M., G. Verschraegen, G. Claeys, and A. M. van den Abeele. 1990. Serological typing of Branhamella catarrhalis strains on the basis of lipooligosaccharide antigens. J. Clin. Microbiol. 28:182-187.
55. Verduin, C. M., C. Hol, A. Fleer, H. van Dijk, and A. van Belkum. 2002. Moraxella catarrhalis: from emerging to established pathogen. Clin. Microbiol. Rev. 15:125-144.
56. Wagner, D. K., M. L. Clements, C. B. Reimer, M. Synder, D. L. Nelson, and B. R. Murphy. 1987. Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum. J. Clin. Microbiol. 25:559-562.
57. Warburg, O., and W. Christian. 1942. Isolation and crystallization of enolase. Biochem. Z. 310:384-421.
58. World Health Organization Expert Committee on Biological Standardization. 1991. Requirements for Haemophilus type b conjugate vaccines. W.H.O. Tech. Rep. Ser. 814:15-37.
59. Yang, Y. P., L. E. Myers, U. McGuinness, P. Chong, Y. Kwok, M. H. Klein, and R. E. Harkness. 1997. The major outer membrane protein, CD, extracted from Moraxella (Branhamella) catarrhalis is a potential vaccine antigen that induces bactericidal antibodies. FEMS Immunol. Med. Microbiol. 17:187-199.